Effect of Progressive Heart Failure on Cerebral Hemodynamics and Monoamine Metabolism in CNS

M L Mamalyga1, L M Mamalyga2

  • 1Department of Human and Animal Anatomy and Physiology, Moscow State Pedagogical University, Moscow, Russia. mamalyga_49@mail.ru.

Insights

Heart failure progression involves brain and heart changes. Decompensated heart failure shows reduced brain blood flow and impaired monoamine synthesis, leading to regulatory system failure.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Biochemistry

Background:

  • Heart failure (HF) presents distinct brain and cardiac disorder patterns in compensated and decompensated stages.
  • Compensated HF maintains normal blood flow in key cerebral arteries (carotid, basilar).
  • Decompensated HF involves significant reductions in cerebral blood flow.

Purpose of the Study:

  • To investigate the relationship between heart failure stages and cerebral blood flow.
  • To analyze changes in brain monoamine content and synthesis capacity at different HF stages.
  • To understand the role of central regulatory mechanisms in HF progression.

Main Methods:

  • Assessing cerebral blood flow in common carotid and basilar arteries.
  • Evaluating brain monoamine levels and synthesis capacity using functional exercise tests.
  • Correlating cerebral hemodynamics and neurochemical changes with HF severity.

Main Results:

  • Cerebral blood flow remains stable in compensated HF but decreases in decompensated HF.
  • Functional exercise tests reveal differential brain monoamine-synthesizing capacities between compensated and decompensated HF.
  • Reduced monoaminergic system capacity is observed in decompensated HF.

Conclusions:

  • Decompensation in heart failure is linked to decreased cerebral blood flow.
  • Impaired brain monoamine synthesis in decompensated HF may overstrain regulatory systems.
  • Failure of compensatory mechanisms, driven by central regulatory exhaustion, contributes to heart failure progression.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
693